IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor
IGC Pharma (NYSE American:IGC) has appointed Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. McAuliffe will focus on refining growth strategies, driving business development, and fostering partnerships with pharmaceutical and healthcare organizations. His expertise in regulatory landscapes and collaborations is expected to accelerate the company's clinical development efforts.
McAuliffe, who was honored as BIO Governor of the Year in 2016, brings experience across banking, public service, and biosciences. The company's main focus is on IGC-AD1, an investigational therapy targeting agitation in Alzheimer's dementia, with preclinical research suggesting potential disease-modifying properties including reduction of amyloid plaques and tau tangles. IGC Pharma is also developing therapies for metabolic disorders like obesity and diabetes while incorporating AI initiatives for drug discovery.
IGC Pharma (NYSE American:IGC) ha nominato Terry McAuliffe, il 72° governatore della Virginia, come consulente strategico. McAuliffe si concentrerà sul perfezionamento delle strategie di crescita, sulla promozione dello sviluppo commerciale e sul rafforzamento delle collaborazioni con le organizzazioni farmaceutiche e sanitarie. La sua esperienza nei contesti normativi e nelle collaborazioni dovrebbe accelerare gli sforzi di sviluppo clinico dell'azienda.
McAuliffe, che è stato nominato BIO Governor of the Year nel 2016, porta con sé esperienza nei settori bancario, dei servizi pubblici e delle bioscienze. Il principale obiettivo dell'azienda è IGC-AD1, una terapia in fase di investigazione mirata a trattare l'agitazione nella demenza di Alzheimer, con ricerche precliniche che suggeriscono potenziali proprietà modificanti la malattia, inclusa la riduzione delle placche amiloidi e dei grovigli di tau. IGC Pharma sta anche sviluppando terapie per i disturbi metabolici come l'obesità e il diabete, integrando iniziative di intelligenza artificiale per la scoperta di farmaci.
IGC Pharma (NYSE American:IGC) ha nombrado a Terry McAuliffe, el 72º gobernador de Virginia, como asesor estratégico. McAuliffe se centrará en perfeccionar las estrategias de crecimiento, impulsar el desarrollo empresarial y fomentar asociaciones con organizaciones farmacéuticas y de salud. Se espera que su experiencia en paisajes regulatorios y colaboraciones acelere los esfuerzos de desarrollo clínico de la empresa.
McAuliffe, quien fue honrado como BIO Governor of the Year en 2016, aporta experiencia en los sectores bancario, servicio público y biosciencias. El enfoque principal de la empresa es IGC-AD1, una terapia en investigación que apunta a la agitación en la demencia de Alzheimer, con investigaciones preclínicas que sugieren potenciales propiedades modificadoras de la enfermedad, incluida la reducción de placas amiloides y enredos de tau. IGC Pharma también está desarrollando terapias para trastornos metabólicos como la obesidad y la diabetes, mientras incorpora iniciativas de IA para el descubrimiento de medicamentos.
IGC Pharma (NYSE American:IGC)는 테리 맥컬리프(Terry McAuliffe)를 버지니아주 72대 주지사로 임명하여 전략 고문으로 활동하게 했습니다. 맥컬리프는 성장 전략을 개선하고 비즈니스 개발을 추진하며 제약 및 헬스케어 조직과의 파트너십을 강화하는 데 집중할 것입니다. 그의 규제 환경 및 협업에 대한 전문성이 회사의 임상 개발 노력을 가속화할 것으로 예상됩니다.
2016년 BIO 올해의 주지사로 선정된 맥컬리프는 은행업, 공공 서비스 및 생명과학 분야에서의 경험을 가지고 있습니다. 회사의 주요 초점은 IGC-AD1로, 알츠하이머 치매의 불안을 겨냥한 연구개발 단계의 치료제이며, 사전임상 연구는 아밀로이드 플라크 및 타우 엉킴 감소를 포함한 질병 수정 가능성을 제시하고 있습니다. IGC Pharma는 비만 및 당뇨병과 같은 대사 장애에 대한 치료법도 개발 중이며, 약물 발견을 위한 AI 이니셔티브를 통합하고 있습니다.
IGC Pharma (NYSE American:IGC) a nommé Terry McAuliffe, le 72ème gouverneur de Virginie, en tant que conseiller stratégique. McAuliffe se concentrera sur le perfectionnement des stratégies de croissance, la promotion du développement commercial et le renforcement des partenariats avec les organisations pharmaceutiques et de santé. Son expertise dans les domaines réglementaires et les collaborations devrait accélérer les efforts de développement clinique de l'entreprise.
McAuliffe, qui a été honoré en tant que BIO Governor of the Year en 2016, apporte une expérience dans les secteurs bancaire, des services publics et des biosciences. L'objectif principal de l'entreprise est IGC-AD1, une thérapie expérimentale visant à traiter l'agitation dans la démence d'Alzheimer, des recherches précliniques suggérant des propriétés modifiant la maladie, notamment la réduction des plaques amyloïdes et des enchevêtrements de tau. IGC Pharma développe également des thérapies pour les troubles métaboliques tels que l'obésité et le diabète, tout en intégrant des initiatives d'IA pour la découverte de médicaments.
IGC Pharma (NYSE American:IGC) hat Terry McAuliffe, den 72. Gouverneur von Virginia, als strategischen Berater ernannt. McAuliffe wird sich darauf konzentrieren, Wachstumsstrategien zu verfeinern, die Geschäftsentwicklung voranzutreiben und Partnerschaften mit Pharma- und Gesundheitsorganisationen zu fördern. Seine Expertise in regulatorischen Landschaften und Kooperationen wird voraussichtlich die klinischen Entwicklungsbemühungen des Unternehmens beschleunigen.
McAuliffe, der 2016 als BIO Governor of the Year ausgezeichnet wurde, bringt Erfahrung aus den Bereichen Bankwesen, öffentlicher Dienst und Biowissenschaften mit. Der Hauptfokus des Unternehmens liegt auf IGC-AD1, einer investigativen Therapie zur Behandlung von Agitation bei Alzheimer-Demenz, wobei präklinische Forschungen auf potenzielle krankheitsmodifizierende Eigenschaften hinweisen, einschließlich der Reduzierung von Amyloid-Plaques und Tau-Verwicklungen. IGC Pharma entwickelt auch Therapien für Stoffwechselstörungen wie Adipositas und Diabetes und integriert KI-Initiativen zur Arzneimittelentwicklung.
- Appointment of high-profile advisor with extensive regulatory and industry experience
- Preclinical research shows IGC-AD1 may reduce amyloid plaques and tau tangles
- Company expanding into metabolic disorders market (obesity and diabetes)
- None.
POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of Virginia, as a strategic advisor. Governor McAuliffe's extensive leadership experience across public and private sectors will play a pivotal role in advancing IGC Pharma's mission to redefine Alzheimer's care and position the Company for growth in the biotechnology and pharmaceutical industries.
As strategic advisor, Governor McAuliffe will focus on refining IGC Pharma's growth strategies, driving business development initiatives, and fostering partnerships with leading pharmaceutical and healthcare organizations. His expertise in navigating complex regulatory landscapes and fostering collaborations is expected to accelerate the Company's clinical development efforts, expand its market footprint, and strengthen engagement with key stakeholders.
Governor McAuliffe's career spans industries such as banking, public service, and biosciences. At the 2016 BIO International Convention, he was honored as BIO Governor of the Year for his commitment to strengthening the biosciences industry. His proven ability to lead transformative initiatives and create sustainable value across sectors makes him a vital addition to IGC Pharma's leadership team.
"Alzheimer's affects over 7 million Americans, and the need for innovative therapies has never been more critical," said Terry McAuliffe. "IGC Pharma's work on effective treatments for Alzheimer's disease and obesity gives real hope to patients and families facing these devastating diseases. I'm proud to join a team leveraging its diverse pipeline to address the greatest healthcare challenges of our time."
"We are excited to welcome Governor McAuliffe to IGC Pharma," said Ram Mukunda, CEO. "His leadership, vision, and breadth of experience will be invaluable as we pursue strategic partnerships, position IGC-AD1 as a transformative therapy in Alzheimer's care, and expand our clinical programs, including the upcoming clinical trials of our metabolic disorder candidates and the integration of artificial intelligence to drive drug discovery. Together, we aim to address unmet medical needs while delivering long-term value for patients, caregivers, and shareholders alike."
IGC Pharma is at the forefront of Alzheimer's innovation with IGC-AD1, an investigational therapy targeting agitation in Alzheimer's dementia. Preclinical research indicates that IGC-AD1 may have disease-modifying potential, including reducing amyloid plaques and tau tangles. Beyond Alzheimer's, IGC Pharma is building a diverse pipeline, exploring therapies for metabolic disorders such as obesity and diabetes while leveraging cutting-edge AI initiatives to enhance drug discovery and development.
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia ("CALMA") associated with Alzheimer's (clinicaltrials.gov, IGC Pharma Phase II). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Q filed with the SEC on August 7, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What is IGC Pharma's IGC-AD1 drug candidate targeting?
How will Terry McAuliffe's appointment impact IGC Pharma's strategy?
What new therapeutic areas is IGC Pharma expanding into beyond Alzheimer's?
What recognition did Terry McAuliffe receive in the biotech industry?
